Recombinant Toxins for Cancer Treatment

Overview

Journal Science

Specialty Science

Date 1991 Nov 22

PMID 1683495

Citations 51

Authors

I Pastan

D Fitzgerald

Affiliations

Soon will be listed here.

Abstract

Recombinant toxins target cell surface receptors and antigens on tumor cells. They kill by mechanisms different from conventional chemotherapy, so that cross resistance to conventional chemotherapeutic agents should not be a problem. Furthermore, they are not mutagens and should not induce secondary malignancies or accelerate progression of benign malignancies. They can be mass-produced cheaply in bacteria as homogeneous proteins. Either growth factor-toxin fusions or antibody-toxin fusions can be chosen, depending on the cellular target.

Citing Articles

Local Delivery Strategies for Peptides and Proteins into the CNS: Status Quo, Challenges, and Future Perspectives.

Yue W, Shen J Pharmaceuticals (Basel). 2023; 16(6).

PMID: 37375758 PMC: 10302941. DOI: 10.3390/ph16060810.

Nanoparticles Functionalised with Re(I) Tricarbonyl Complexes for Cancer Theranostics.

Mkhatshwa M, Moremi J, Makgopa K, Manicum A Int J Mol Sci. 2021; 22(12).

PMID: 34207182 PMC: 8235741. DOI: 10.3390/ijms22126546.

Natural and Designed Toxins for Precise Therapy: Modern Approaches in Experimental Oncology.

Shilova O, Shramova E, Proshkina G, Deyev S Int J Mol Sci. 2021; 22(9).

PMID: 34067057 PMC: 8124712. DOI: 10.3390/ijms22094975.

Depletion of Gut-Resident CCR5 Cells for HIV Cure Strategies.

Merriam D, Chen C, Mendez-Lagares G, Rogers K, Michaels A, Yan J AIDS Res Hum Retroviruses. 2017; 33(S1):S70-S80.

PMID: 28918646 PMC: 5684671. DOI: 10.1089/aid.2017.0159.

The potential roles of bacteria to improve radiation treatment outcome.

Kouhsari E, Ghadimi-Daresajini A, Abdollahi H, Amirmozafari N, Mahdavi S, Abbasian S Clin Transl Oncol. 2017; 20(2):127-139.

PMID: 28623514 DOI: 10.1007/s12094-017-1701-7.